US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Notice of annual general meeting in Biosergen AB

The shareholders of Biosergen AB, Reg. No. 559304-1295, (the "Company") are invited to attend the annual general meeting to be held on June 30, 2026, at 14:00 at BAHR Advokatbyrå at Birger Jarlsgatan 16, SE-114 34, Stockholm. Registration for the meeting begins at 13:30.Right to participate Shareholders wishing to participate in the annual general meeting must: · be listed in the Company's share register kept by Euroclear Sweden AB as of June 22, 2026; and · have given a notice of their intent to participate to the Company no later than on June 24, 2026. The notification should

Biosergen Pauses Development of BSG005

PRESS RELEASESTOCKHOLM, APRIL 4th 2026Against the backdrop of a continued challenging financing environment, the Board of Directors of Biosergen AB (OMX: BIOSGN) has today resolved to pause the development of BSG005. As disclosed in previous quarterly reports, the manufacture of new drug substance has resulted in delays in the development of Biosergen’s product candidate BSG005. The year-end report published on 10 February 2026 stated that the company’s financial position needs to be strengthened in order to ensure continued operations. Despite extensive efforts, the company has not been

Biosergen publishes interim report for the fourth quarter 2025

February 10, 2026: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the fourth quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net) Advancing BSG005 Toward Cohort 3 and Strengthening Key Program Foundations Progress in GMP Manufacturing of BSG005 and Successful Pre-IND meeting with good guidance from FDA“During the fourth quarter, our primary operational focus remained on preparing the BSG005 program for its next phase of advancement. In particular finalization of drug supply to ensure

Determination of Record Date for Reverse Share Split in Biosergen

STOCKHOLM, November 20, 2025. At the Annual General Meeting of Biosergen AB (“Biosergen” or the “Company”) on June 11, 2025, a resolution was passed on a reverse split of shares, whereby one hundred (100) existing shares are reversed into one (1) share (reversal ratio 1:100). The Board of Directors was further authorized to determine the record date for the reverse split. Biosergen’s Board of Directors has today resolved that the record date for the reverse split shall be December 2, 2025.Through the reverse share split, the total number of shares in the Company will decrease from 234,823,

Biosergen publishes interim report for the third quarter 2025

November 19, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net)  Advancing BSG005 Toward Cohort 3 and Key Appointments  Progress in GMP Manufacturing of BSG005 and U.S. IND Submission Preparations“During the third quarter of 2025, we focused on preparing for the next phase of BSG005’s development. The manufacturing of a new GMP-compliant batch is progressing according to plan and will support both Cohort 3 and our

Biosergen’s Nomination Committee appointed

STOCKHOLM, October 28th, 2025 – In accordance with the resolution of the Annual General Meeting on June 11th, 2025, the Chairman of the Board has contacted the company’s two largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee.Biosergen’s Nomination Committee ahead of the Annual General Meeting for the fiscal year January – December 2025 comprises:   • Eric Strandqvist, appointed by

Biosergen publishes its interim report for the second quarter 2025

Wednesday August 20, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the second quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net)Advancing BSG005 Toward Cohort 3 and Key Appointments“During the second quarter of 2025, we made solid progress on several key fronts. Manufacturing a new GMP-compliant batch of BSG005 is underway to support the start of Cohort 3 later this year and the phase 2/3 program. At the same time, we continued our regulatory discussions in India and advanced

Biosergen Appoints Mark Beveridge as Chief Financial Officer

Stockholm, Sweden – July 24, 2025 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces the appointment of Mark Beveridge as its new Chief Financial Officer. Mark succeeds Niels Laursen, who will remain with the Company during a transition period to ensure continuity and support a smooth handover.“We are very pleased to welcome Mark to Biosergen’s leadership team,” said Tine K. Olesen, CEO of Biosergen. “He brings extensive financial expertise and a proven track record in supporting

Bulletin from the annual general meeting in Biosergen AB (publ)

At the annual general meeting in Biosergen AB (publ) (the “Company”) held today, June 11, 2025, the below resolutions were adopted. All resolutions were adopted in accordance with the presented proposals, which are described in detail in the notice to the annual general meeting available on the Company’s website, www.biosergen.net.Resolution on adoption of accounts and allocation of the Company’s profits The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The

Biosergen publishes interim report for the first quarter 2025

May 21, 2025: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for first quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net)BSG005 Demonstrates Therapeutic Effect in High-Risk Patients: Cohort 2 Completed2025 will be the year we focus on expanding the clinical path for BSG005 beyond India—by preparing for FDA pre-IND meeting and establishing a future-proof production setup for BSG005—while also progressing toward Phase 2 planning in India. These activities are already in motion, driven by the

Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives

Stockholm, Sweden – May 9, 2025 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces  the proposal of electing Dr. Marco Taglietti, M.D., as a new member of the Board of Directors ahead of the upcoming Annual General Meeting.The proposal is made in light of the Company’s continued promising clinical development of its antifungal drug candidate, BSG005, which is currently being investigated in a proof-of-concept trial as a rescue therapy for patients who have failed previous standard-

Notice of annual general meeting in Biosergen AB

The shareholders of Biosergen AB, Reg. No. 559304-1295, (the “Company”) are invited to attend the annual general meeting to be held on Wednesday June 11, 2025, at Fogdevreten 2A, SE-171 65 Solna, at 11:00.Right to participate and notice of participation Shareholders wishing to participate in the annual general meeting must: · be listed in the Company’s share register kept by Euroclear Sweden AB as of Monday June 2, 2025; and · have given a notice of their intent to participate to the Company no later than on Wednesday June 4, 2025 by post to Advokatfirman Hammarskiöld & Co, Att:

BioStock: Biosergen takes aim at climate-driven fungal infections

Research shows that climate change is driving the rapid spread of Aspergillus, a mold causing deadly infections. Rising temperatures, extreme weather, and elevated CO2 levels create ideal conditions for fungal proliferation, threatening vulnerable populations worldwide. To address this, Biosergen is developing BSG005, a novel antifungal with potent, broad-spectrum efficacy and a strong safety profile.Read the article at biostock.se: https://www.biostock.se/en/2025/05/biosergen-takes-aim-at-climate-driven-fungal-infections/ This is a press release from BioStock - Connecting Innovation &

BioStock: Biosergen’s CEO on the latest advancements

As fungal infections continue to be recognized as a growing global health problem, Biosergen is sharpening its focus. The company’s recently published annual report highlights the clinical progress made in 2024 and its priorities in addressing an area with significant unmet medical needs. We contacted CEO Tine Olesen for a comment.Read the interview at biostock.se: https://www.biostock.se/en/2025/05/biosergens-ceo-on-the-latest-advancements/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Biosergen scales up for future wins

Biosergen is charging into 2025 with momentum, building on a transformative 2024 that showcased the life-saving potential of its antifungal drug candidate, BSG005. As the biotech company continues its mission to combat the global crisis of life-threatening fungal infections, it is focused on key strategic priorities for the year ahead expanding clinical trials, accelerating development, and strengthening its global presence.Read the article at biostock.se: https://www.biostock.se/en/2025/03/biosergen-scales-up-for-future-wins/This is a press release from BioStock - Connecting

Biosergen publishes interim report for fourth quarter 2024

March 5, 2025: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for fourth quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net2025: STRENGTHENING BIOSERGEN’S POSITION FOR GLOBAL TRIALS2025 will be the year we expect to initiate substantial discussions with the U.S. FDA on securing an Investigational New Drug (IND) application for BSG005—an essential step toward conducting clinical trials in the U.S. We plan to enter these discussions with strong clinical data from our ongoing trial in India and

BioStock: Biosergen’s CEO: “These findings open up new possibilities”

Biosergen’s antifungal drug candidate, BSG005, continues to show strong clinical potential. The majority of the patients in the second cohort either fully recovered or significantly improved, consistent with earlier results. With these encouraging outcomes, Biosergen is advancing key regulatory and development plans for BSG005. BioStock reached out to CEO Tine Olesen to get her comments on this achievement.“Every opportunity to gain time or market share is being thoroughly explored”, says Tine.Read the interview with CEO Tine Olesen at biostock.se: https://www.biostock.se/en/2025/02/

Biosergen Successfully Completes Second Cohort of BSG005 Clinical Trial, Gaining Conclusive Proof-of-Concept Data, and Confirms 2025 Objectives

February 4, 2025 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announced the successful completion of treatment for the second cohort of patients in its proof-of-concept clinical trial for its antifungal drug candidate, BSG005.In general, the patients in Cohort 2 were in an even worse condition at the time of enrollment compared to those in Cohort 1. The cohort consisted of five patients with life-threatening fungal infections: one completely recovered, three showed significant improvements, and one

Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial

December 20, 2024 – Stockholm, Sweden – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, announces that the independent Data Safety Review Board that is monitoring the safety and efficacy of the current clinical study, has agreed to allow investigators to exceed the previously established maximum dose of 1.5 mg/kg/day in the ongoing second cohort of its clinical trial for BSG005. This decision was made following a request from the Principal Investigator, supported by compelling preliminary data, reflecting the

Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3

The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 5, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, resolved on a directed issue of 734,963 shares to such underwriters in the warrant program who have chosen to receive underwriting compensation in the form of newly issued shares in the Company (the "Compensation

Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3

The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 3, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, decided on a directed share issue of 6,348,670 shares (the "Directed Issue") to a number of investors ("the Underwriters"). The subscription price in the Directed Issue is SEK 0.49, which corresponds to the

Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3

Biosergen AB (”Biosergen” or the "Company") announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with a rights issue in the Company during the first quarter 2024. In total, 91,701,328 warrants of series TO3 were exercised, corresponding to 100.0 percent of the total number of outstanding warrants of series TO3, for subscription of 91,701,328 shares at an exercise price of SEK 0.49 per share. Biosergen will receive approximately SEK 44.9 million before issuing costs through the exercise of the warrants of series TO3. Upon the exercise period

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe